SAGE Therapeutics (SAGE) Misses Q3 EPS by 69c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($3.37), $0.69 worse than the analyst estimate of ($2.68). Revenue for the quarter came in at $2.72 million versus the consensus estimate of $4.63 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance